PMID- 31819371
OWN - NLM
STAT- MEDLINE
DCOM- 20200603
LR  - 20220411
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 13
DP  - 2019
TI  - A Network Pharmacology-Based Strategy For Predicting Active Ingredients And 
      Potential Targets Of LiuWei DiHuang Pill In Treating Type 2 Diabetes Mellitus.
PG  - 3989-4005
LID - 10.2147/DDDT.S216644 [doi]
AB  - BACKGROUND: Traditional Chinese medicine (TCM) formulations have proven to be 
      advantageous in clinical treatment and prevention of disease. LiuWei DiHuang Pill 
      (LWDH Pill) is a TCM that was employed to treat type 2 diabetes mellitus (T2DM). 
      However, a holistic network pharmacology approach to understanding the active 
      ingredients and the therapeutic mechanisms underlying T2DM has not been pursued. 
      METHODS: A network pharmacology approach including drug-likeness evaluation, oral 
      bioavailability prediction, virtual docking, and network analysis has been used 
      to predict the active ingredients and potential targets of LWDH Pill in the 
      treatment of type 2 diabetes. RESULTS: The comprehensive network pharmacology 
      approach was successfully to identify 45 active ingredients in LWDH Pill. 45 
      active ingredients hit by 163 potential targets related to T2DM. Ten of the more 
      highly predictive components (such as :quercetin, Kaempferol, Stigmasterol, 
      beta-sitosterol, Kadsurenone, Diosgenin, hancinone C, Hederagenin, Garcinone B, 
      Isofucosterol) are involved in anti-inflammatory, anti-oxidative stress, and the 
      reduction of beta cell damage. LWDH Pill may play a role in the treatment of T2DM 
      and its complications (atherosclerosis and nephropathy) through the AGE-RAGE 
      signaling pathway, TNF signaling pathway, and NF-kappa B signaling pathway. 
      CONCLUSION: Based on a systematic network pharmacology approach, our works 
      successfully predict the active ingredients and potential targets of LWDH Pill 
      for application to T2DM and helps to illustrate mechanism of action on a 
      comprehensive level. This study provides identify key genes and pathway 
      associated with the prognosis and pathogenesis of T2DM from new insights, which 
      also demonstrates a feasible method for the research of chemical basis and 
      pharmacology in LWDH Pill.
CI  - (c) 2019 He et al.
FAU - He, Dan
AU  - He D
AD  - Hunan Academy of Chinese Medicine, Hunan University of Chinese Medicine, 
      Changsha, Hunan 410013, People's Republic of China.
FAU - Huang, Jian-Hua
AU  - Huang JH
AD  - Hunan Academy of Chinese Medicine, Hunan University of Chinese Medicine, 
      Changsha, Hunan 410013, People's Republic of China.
AD  - Hunan Key Laboratory of TCM Prescription and Syndromes Translational Medicine, 
      Changsha, Hunan 410208, People's Republic of China.
AD  - 2011 Collaboration and Innovation Center for Digital Chinese Medicine in Hunan, 
      Changsha 410013, People's Republic of China.
FAU - Zhang, Zhe-Yu
AU  - Zhang ZY
AD  - Department of Gastroenterology, Xiangya Hospital, Central South University, 
      Changsha, Hunan 410008, People's Republic of China.
FAU - Du, Qing
AU  - Du Q
AD  - Hunan Academy of Chinese Medicine, Hunan University of Chinese Medicine, 
      Changsha, Hunan 410013, People's Republic of China.
FAU - Peng, Wei-Jun
AU  - Peng WJ
AUID- ORCID: 0000-0002-4506-0942
AD  - Department of Gastroenterology, Xiangya Hospital, Central South University, 
      Changsha, Hunan 410008, People's Republic of China.
FAU - Yu, Rong
AU  - Yu R
AD  - Hunan Academy of Chinese Medicine, Hunan University of Chinese Medicine, 
      Changsha, Hunan 410013, People's Republic of China.
AD  - Hunan Key Laboratory of TCM Prescription and Syndromes Translational Medicine, 
      Changsha, Hunan 410208, People's Republic of China.
FAU - Zhang, Si-Fang
AU  - Zhang SF
AD  - Department of Gastroenterology, Xiangya Hospital, Central South University, 
      Changsha, Hunan 410008, People's Republic of China.
FAU - Zhang, Shui-Han
AU  - Zhang SH
AD  - Hunan Academy of Chinese Medicine, Hunan University of Chinese Medicine, 
      Changsha, Hunan 410013, People's Republic of China.
FAU - Qin, Yu-Hui
AU  - Qin YH
AD  - Hunan Academy of Chinese Medicine, Hunan University of Chinese Medicine, 
      Changsha, Hunan 410013, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20191128
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Liuwei Dihuang Decoction)
SB  - IM
EIN - Drug Des Devel Ther. 2020 Mar 02;14:949. PMID: 32184563
MH  - Cluster Analysis
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drugs, Chinese Herbal/chemistry/isolation & purification/*therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/chemistry/isolation & purification/*therapeutic use
PMC - PMC6890936
OTO - NOTNLM
OT  - LWDH Pill
OT  - T2DM
OT  - network pharmacology
OT  - type 2 diabetes mellitus
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/12/11 06:00
MHDA- 2020/06/04 06:00
PMCR- 2019/11/28
CRDT- 2019/12/11 06:00
PHST- 2019/05/22 00:00 [received]
PHST- 2019/09/27 00:00 [accepted]
PHST- 2019/12/11 06:00 [entrez]
PHST- 2019/12/11 06:00 [pubmed]
PHST- 2020/06/04 06:00 [medline]
PHST- 2019/11/28 00:00 [pmc-release]
AID - 216644 [pii]
AID - 10.2147/DDDT.S216644 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2019 Nov 28;13:3989-4005. doi: 10.2147/DDDT.S216644. 
      eCollection 2019.